Hepatology News
| Jul 24, 2008 – SOURCE: Journal of Viral Hepatitis | |||
 |
|
A continuous (13)C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT | |
| Up to 30% of patients with hepatitis C virus (HCV) infection and normal serum alanine aminotransferase (NALT) have significant liver disease. Currently, many of these patients undergo a liver biopsy to guide therapeutic decisions. The BreathID((R)) contin | |||
| Jul 24, 2008 – SOURCE: Journal of Hepatology | |||
|
|
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection | |
| BACKGROUND/AIMS: Intercross studies in inbred mice susceptible or resistant to liver fibrosis revealed complement factor 5 as a quantitative trait gene associated with the development of fibrosis. In 277 patients with hepatitis C, two C5 SNPs, rs17611 and | |||
| Jul 24, 2008 – SOURCE: Journal of Surgical Oncology | |||
|
|
Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma | |
| BACKGROUND: Interferon therapy might reduce recurrence after resection of hepatitis C virus-related hepatocellular carcinoma, especially among sustained virologic or biochemical responders. METHODS: Of 209 patients who underwent curative resection for ear | |||
| Jul 24, 2008 – SOURCE: Ophthalmic Plastic and Reconstructive Surgery (OPRS) | |||
|
|
Sarcoid-like Granulomatous Orbital Inflammation Induced by Interferon-alpha Treatment | |
| A 56-year-old black woman presented with bilateral orbital swelling in the lacrimal gland region 4 months after initiation of interferon-alpha and ribavirin treatment for occupationally-acquired hepatitis C infection. Histopathologic evaluation of bilater | |||
| Jul 24, 2008 – SOURCE: Archives of Surgery | |||
|
|
Liver transplant for hepatitis C virus: effect of using older donor grafts on short- and medium-term survival | |
| HYPOTHESIS: Older donor grafts will provide suitable results of liver transplant, even in recipients with hepatitis C virus (HCV). Although HCV remains the leading indication for liver transplant in adults in the United States, it is associated with HCV r | |||
| Jul 23, 2008 – SOURCE: Infection | |||
|
|
Therapeutical Aspects and Outcome of HIV/HCV Coinfected Patients Treated with Pegylated Interferon plus Ribavirin in an Italian Cohort | |
| BACKGROUND: One-third of HIV-infected individuals suffer from chronic hepatitis C virus infection (HCV) in Europe. Recommendations from HCV-HIV International Panel advise current treatment with pegylated interferon plus ribavirin. We assessed the impact o | |||
| Jul 22, 2008 – SOURCE: DGNews | |||
|
|
TopAbstracts in Hepatitis C 07/22/2008 | |
| TopAbstracts - Past 14 days |
|||
| Jul 22, 2008 – SOURCE: Journal of Viral Hepatitis | |||
|
|
Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients | |
| Reluctance has been expressed about treating chronic hepatitis C in active intravenous (IV) drug users (IDUs), and this is found in both international guidelines and routine clinical practice. However, the medical literature provides no evidence for an un | |||
| Jul 21, 2008 – SOURCE: DGNews | |||
|
|
Livers From Elderly Donors Safe, Effective for Recipients With Hepatitis C | |
| CHICAGO -- July 21, 2008 -- Receiving a liver from a donor aged 60 years and older does not appear to be associated with transplant failure, death, or recurrent disease in the next 5 years among transplant recipients with hepatitis C, according to a study | |||
| Jul 21, 2008 – SOURCE: Journal of Viral Hepatitis | |||
|
|
Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin | |
| Serum ribavirin concentration is an important factor in antiviral therapy in combination with peginterferon (PEG-IFN) and ribavirin for patients with chronic hepatitis C in terms of both beneficial and adverse effects. We evaluated whether the serum ribav | |||
